Marcio Nucci1, Simone A Nouér2, Patricia Esteves3, Thais Guimarães4, Giovanni Breda5, Bianca Grassi de Miranda4, Flavio Queiroz-Telles5, Arnaldo L Colombo3. 1. University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil mnucci@hucff.ufrj.br. 2. University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 3. University Hospital, Universidade Federal de São Paulo, São Paulo, Brazil. 4. Hospital do Servidor Publico de São Paulo, São Paulo, Brazil. 5. University Hospital, Universidade Federal do Paraná, Curitiba, Brazil.
Abstract
BACKGROUND: Empirical antifungal therapy in high-risk ICU patients is an attractive strategy, but overuse of antifungal agents is a potential problem. OBJECTIVES: We evaluated if ICU patients at high risk to develop candidaemia identified by a prediction rule could discontinue empirical antifungal therapy on the basis of repeatedly negative 1-3-β-d-glucan (BDG) tests. METHODS: We conducted a multicentre cohort study in 85 ICU patients receiving antibiotics or with central venous catheter plus two additional factors (dialysis, parenteral nutrition, surgery, pancreatitis or receipt of corticosteroids or other immunosuppressive agents) plus either fever, hypothermia, hypotension, acidosis, elevated C-reactive protein or leucocytosis. Blood cultures (days 1 and 2) and BDG (days 1-3, baseline period) were performed and anidulafungin was given. On day 4, patients with negative blood cultures and BDG discontinued antifungal therapy. Registered in ClinicalTrials.gov (NCT01734525). RESULTS: The incidence of candidaemia was 8.2% in patients selected versus 0.5% in patients without entry criteria (16.9 times higher). Sixty-four patients (75.3%) had baseline positive BDG, including 7 with candidaemia. All 21 patients with baseline negative BDG discontinued anidulafungin on day 4. None developed candidaemia until day 30. CONCLUSIONS: Early discontinuation of empirical echinocandin therapy in high-risk ICU patients based on consecutive negative BDG tests may be a reasonable strategy, with great potential to reduce the overuse of echinocandins in ICU patients. Prospective studies with a higher number of patients are needed.
BACKGROUND: Empirical antifungal therapy in high-risk ICU patients is an attractive strategy, but overuse of antifungal agents is a potential problem. OBJECTIVES: We evaluated if ICU patients at high risk to develop candidaemia identified by a prediction rule could discontinue empirical antifungal therapy on the basis of repeatedly negative 1-3-β-d-glucan (BDG) tests. METHODS: We conducted a multicentre cohort study in 85 ICU patients receiving antibiotics or with central venous catheter plus two additional factors (dialysis, parenteral nutrition, surgery, pancreatitis or receipt of corticosteroids or other immunosuppressive agents) plus either fever, hypothermia, hypotension, acidosis, elevated C-reactive protein or leucocytosis. Blood cultures (days 1 and 2) and BDG (days 1-3, baseline period) were performed and anidulafungin was given. On day 4, patients with negative blood cultures and BDG discontinued antifungal therapy. Registered in ClinicalTrials.gov (NCT01734525). RESULTS: The incidence of candidaemia was 8.2% in patients selected versus 0.5% in patients without entry criteria (16.9 times higher). Sixty-four patients (75.3%) had baseline positive BDG, including 7 with candidaemia. All 21 patients with baseline negative BDG discontinued anidulafungin on day 4. None developed candidaemia until day 30. CONCLUSIONS: Early discontinuation of empirical echinocandin therapy in high-risk ICU patients based on consecutive negative BDG tests may be a reasonable strategy, with great potential to reduce the overuse of echinocandins in ICU patients. Prospective studies with a higher number of patients are needed.
Authors: Matteo Bassetti; Jose Garnacho-Montero; Thierry Calandra; Bartjan Kullberg; George Dimopoulos; Elie Azoulay; Arunaloke Chakrabarti; Daniel Kett; Cristobal Leon; Luis Ostrosky-Zeichner; Maurizio Sanguinetti; Jean-Francois Timsit; Malcom D Richardson; Andrew Shorr; Oliver A Cornely Journal: Intensive Care Med Date: 2017-03-02 Impact factor: 17.440
Authors: Robert L D'Ordine; Kevin A Garcia; Josee Roy; Yonglong Zhang; Barbara Markley; Malcolm A Finkelman Journal: Med Mycol Date: 2021-01-04 Impact factor: 4.076
Authors: Gennaro De Pascale; Brunella Posteraro; Sonia D'Arrigo; Giorgia Spinazzola; Rita Gaspari; Giuseppe Bello; Luca Maria Montini; Salvatore Lucio Cutuli; Domenico Luca Grieco; Valentina Di Gravio; Giulia De Angelis; Riccardo Torelli; Elena De Carolis; Mario Tumbarello; Maurizio Sanguinetti; Massimo Antonelli Journal: Crit Care Date: 2020-09-05 Impact factor: 9.097